trial

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

NCTId NCT00088478
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 402 (actual)
Sponsored by Eli Lilly and Company
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
402 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-06
Primary completion
—
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

37 total
National City, United StatesOrange, United StatesRosemead, United StatesSan Diego, United StatesSanta Ana, United StatesDenver, United StatesWashington D.C., United StatesBradenton, United StatesHonolulu, United StatesChicago, United StatesHoffman Estates, United StatesLake Charles, United States

Facts & assertions

3 sourced
Enrollment
402
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person